Truvada

RSS

emtricitabine / tenofovir disoproxil

Authorised
This medicine is authorised for use in the European Union.

Overview

Truvada is used in combination with at least one other HIV medicine to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). In addition it may be used from the age of 12 in adolescents with HIV who are resistant to first-line treatments or who cannot take them because of side effects.

Truvada is also used to help prevent sexually transmitted HIV-1 infection in adults and adolescents who are at high risk of being infected (pre-exposure prophylaxis or PrEP). It should be used in combination with safer sex practices, such as use of condoms.

Truvada contains two active substances, emtricitabine (200 mg) and tenofovir disoproxil (245 mg).

This EPAR was last updated on 02/02/2023

Authorisation details

Product details
Name
Truvada
Agency product number
EMEA/H/C/000594
Active substance
  • emtricitabine
  • tenofovir disoproxil fumarate
International non-proprietary name (INN) or common name
  • emtricitabine
  • tenofovir disoproxil
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
J05AR03
Publication details
Marketing-authorisation holder
Gilead Sciences Ireland UC
Revision
46
Date of issue of marketing authorisation valid throughout the European Union
20/02/2005
Contact address

IDA Business & Technology Park
Carrigtohill
County Cork
T45 DP77
Ireland

Product information

12/01/2023 Truvada - EMEA/H/C/000594 - WS/2320

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Treatment of HIV-1 infection:

  • Truvada is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults.
  • Truvada is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years.

Pre-exposure prophylaxis (PrEP):

  • Truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
Average
1 rating
1 rating
1 rating